-
Non Regulatory December 19, 2024Vivesto strengthens Cantrixil program with new preclinical results and patent application
-
Non Regulatory November 11, 2024Vivesto’s Paccal Vet receives Limited Market classification in EU
-
Regulatory November 7, 2024Vivesto signs Apealea option agreement with Zhida Pharmaceutical
Vivesto published its Q3 report for 2024 on November 21, 2024, at 08.00 am CET.